A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study Investigating PRA-216 in Healthy Volunteers Followed by a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study in Participants With Mild-to-Moderate Asthma
Latest Information Update: 02 Dec 2025
At a glance
- Drugs PRA 216 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Prana Therapies
Most Recent Events
- 02 Dec 2025 New trial record